113 related articles for article (PubMed ID: 17085306)
1. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
Piñana JL; Valcárcel D; Martino R; Moreno ME; Sureda A; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1135-41. PubMed ID: 17085306
[TBL] [Abstract][Full Text] [Related]
2. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
[TBL] [Abstract][Full Text] [Related]
6. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
9. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
10. Pentostatin in steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
[TBL] [Abstract][Full Text] [Related]
11. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease.
Knop S; Hebart H; Gscheidle H; Holler E; Kolb HJ; Niederwieser D; Einsele H
Bone Marrow Transplant; 2005 Nov; 36(9):831-7. PubMed ID: 16151429
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
Lu J; Xu LP; Huang XJ; Chen H; Zhang YC; Ren HY; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):216-9. PubMed ID: 12812665
[TBL] [Abstract][Full Text] [Related]
15. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.
Xhaard A; Rocha V; Bueno B; de Latour RP; Lenglet J; Petropoulou A; Rodriguez-Otero P; Ribaud P; Porcher R; Socié G; Robin M
Biol Blood Marrow Transplant; 2012 Mar; 18(3):406-13. PubMed ID: 21736868
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.
Hui CH; Sia H; Mangos H; Horvath N; Lee H; Lewis I; Hughes T; To LB; Bardy P
Bone Marrow Transplant; 2008 Feb; 41(4):409-10. PubMed ID: 18026147
[No Abstract] [Full Text] [Related]
17. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
[TBL] [Abstract][Full Text] [Related]
19. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.
de Lavallade H; Mohty M; Faucher C; Fürst S; El-Cheikh J; Blaise D
Haematologica; 2006 Oct; 91(10):1438-40. PubMed ID: 16963392
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide.
Mayer J; Krejci M; Pospisil Z; Doubek M; Janikova A; Zackova D; Racil Z; Smardova L; Navratil M; Kamelander J
Exp Hematol; 2009 Jun; 37(6):767-73. PubMed ID: 19463776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
